A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Name: A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Creator: Vivli
Published: 2025-12-05T14:10:29+08:00

DataCite Commons2025-12-05 更新2026-05-07 收录

2型糖尿病治疗

胰岛素给药方案

数据链接：

https://search.vivli.org/doiLanding/studies/PR00012013/isLanding 数据链接链接失效反馈

官方服务：

资源简介：

This trial is conducted in Asia. The aim of the trial is to compare efficacy and safety of thrice daily versus twice daily NovoMix® 30 (Biphasic insulin aspart 30) in subjects with type 2 diabetes inadequately controlled with basal insulin.

提供机构：

Vivli

创建时间：

2025-12-05